RNC Capital Management LLC Boosts Stock Holdings in Gilead Sciences, Inc. $GILD

RNC Capital Management LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.6% during the 4th quarter, Holdings Channel reports. The fund owned 451,991 shares of the biopharmaceutical company’s stock after purchasing an additional 6,947 shares during the quarter. Gilead Sciences makes up approximately 2.5% of RNC Capital Management LLC’s investment portfolio, making the stock its 15th biggest position. RNC Capital Management LLC’s holdings in Gilead Sciences were worth $55,477,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Massachusetts Financial Services Co. MA increased its stake in shares of Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after buying an additional 4,113,999 shares during the period. Vanguard Group Inc. increased its stake in Gilead Sciences by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the last quarter. First Trust Advisors LP raised its holdings in Gilead Sciences by 154.3% during the third quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after purchasing an additional 1,874,508 shares in the last quarter. Invesco Ltd. raised its holdings in Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares in the last quarter. Finally, Danske Bank A S purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $133,049,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the sale, the chief executive officer owned 613,912 shares in the company, valued at approximately $92,086,800. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the chief financial officer directly owned 176,191 shares in the company, valued at approximately $24,835,883.36. The trade was a 1.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 178,640 shares of company stock worth $26,584,250 in the last three months. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of several research analyst reports. Morgan Stanley upped their target price on shares of Gilead Sciences from $171.00 to $175.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. Truist Financial boosted their price target on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Argus upped their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Jefferies Financial Group assumed coverage on Gilead Sciences in a report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective on the stock. Finally, JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $157.35.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $132.69 on Tuesday. The firm has a market cap of $164.70 billion, a P/E ratio of 19.60, a P/E/G ratio of 1.74 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $95.29 and a 52-week high of $157.29. The business’s 50-day moving average price is $140.49 and its 200 day moving average price is $132.55. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same period last year, the firm earned $1.90 EPS. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were issued a dividend of $0.82 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend was Friday, March 13th. Gilead Sciences’s dividend payout ratio is 48.45%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.